Market Overview

BiondVax to Present at Influenza 2018 Oxford Conference


BiondVax to Present at Influenza 2018 Oxford Conference

PR Newswire

JERUSALEM, Sept. 4, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present at the Influenza 2018 Oxford conference at the University of Oxford.

BiondVax Pharmaceuticals Logo (PRNewsfoto/Biondvax Pharmaceuticals Ltd)

Joshua Phillipson, BiondVax's Business Development Manager, will provide an overview of the Company's clinical development achievements and plans, including the recently launched pivotal, clinical efficacy, Phase 3 trial.

Details of Mr. Phillipson's talk:
Getting Closer to the Market: M-001 Universal Flu Vaccine Starting Pivotal Phase 3 Trial
Date: Wednesday, September 5, 2018
Time: 10:40am
Location: Vernon Harcourt Room, South Building, St Hilda's College, University of Oxford, UK.

About BiondVax
BiondVax (NASDAQ:BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-season protection against current and future, seasonal and pandemic influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common influenza virus peptides, activating both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 6 completed Phase 1/2 and Phase 2 human clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic.

Please visit

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the prosecution and outcome of the ongoing Phase 2 and Phase 3 trials and any subsequent trials; timing of receipt of regulatory approval of the new manufacturing facility its products; ability to demonstrate the efficacy and safety of the vaccine; the timing of clinical trials and marketing approvals; the risk that drug development involves a lengthy and expensive process with uncertain outcome; the ability of the Company to maintain, preserve and defend its intellectual property and patents granted; whether our  vaccine candidate will successfully advance through the clinical trial process on a timely basis, or at all, and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; the adequacy of available cash resources and the ability to raise capital when needed. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website,, and in the Company's periodic filings with the SEC and the Tel-Aviv Stock Exchange. We undertake no obligation to revise or update any forward-looking statement for any reason.

Contact Details
Joshua E. Phillipson
+972 8 930 2529


Cision View original content with multimedia:

SOURCE BiondVax Pharmaceuticals Ltd.

View Comments and Join the Discussion!